FDA 483 - Apotex Inc. - September 14, 2022

During an inspection of Apotex Inc. in Richmond Hill, FDA investigators observed that the firm's procedures for preventing microbiological contamination of sterile drug products were not adequately established. Specifically, the firm failed to properly define and document responses to critical interventions on its sterile filling line, which could compromise product sterility.